AOD-9604 in Adolescents (Ages 12 to 17): Off-Label Use, Safety Evidence, and Clinical Guidance

What Is AOD-9604 and Why Is It Being Considered in Adolescents?

AOD-9604 is a synthetic peptide comprising amino acids 176 to 191 of the human growth hormone (hGH) sequence. Researchers originally isolated this fragment because it appeared to reproduce hGH's fat-mobilizing activity without stimulating IGF-1, the mediator of hGH's growth-promoting effects. That selective profile generated early interest in obesity pharmacology.

The drug never reached regulatory approval. Its most advanced adult trial, the CP-METOB program, failed to meet its primary endpoint. Despite this, compounding pharmacies began offering AOD-9604 subcutaneously, and interest has spread to adolescent weight management partly because parents and practitioners feel approved options are limited for teens. That premise is now outdated: the FDA approved semaglutide 2.4 mg (Wegovy) for adolescents aged 12 and older in December 2022, following the STEP TEENS trial [1].

The Regulatory History in Brief

AOD-9604 received Australian Therapeutic Goods Administration (TGA) Investigational New Drug status in the early 2000s for adult obesity. No equivalent FDA IND for pediatric use has ever been publicly registered. The FDA's current position treats AOD-9604 as an unapproved new drug when sold for therapeutic use [2].

Why Adolescents Are Being Targeted

Pediatric obesity affects approximately 19.7% of U.S. Children and adolescents aged 2 to 19, according to CDC National Health and Nutrition Examination Survey data [3]. Families searching for solutions beyond lifestyle modification often encounter compounded peptides online. AOD-9604 is marketed in some forums as "growth-hormone-based but safe" because of its purported IGF-1 neutrality, a claim that has not been tested in any published adolescent cohort.

The Evidence Base: What Clinical Data Actually Exist?

The honest answer is short. No published, peer-reviewed clinical trials have enrolled adolescents aged 12 to 17 to receive AOD-9604 in any dose, route, or duration.

Adult Trial Results and Their Limits

The most cited human data come from a series of Australian Phase II trials in adults with obesity. The largest, sometimes referenced as the CP-METOB study, enrolled approximately 300 adult participants and tested oral AOD-9604 at doses ranging from 1 mg to 9 mg daily over 24 weeks. The trial did not demonstrate statistically significant weight reduction compared with placebo [4]. A 2004 publication by Heffernan and colleagues in the journal Molecular and Cellular Endocrinology described AOD-9604's lipolytic mechanism in rodent models and acknowledged that human translation remained unproven [5].

Because even adult evidence failed to reach a positive primary endpoint, extrapolating any benefit to adolescents is not supported by the data hierarchy used in evidence-based medicine. The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline on Obesity explicitly recommends against using pharmacologic agents without adequate pediatric safety and efficacy data [6].

Animal Data: Promising but Not Transferable

Multiple rodent studies documented reductions in adipose tissue and body weight with AOD-9604 administration. A 2001 paper by Ng and colleagues in the American Journal of Physiology reported reduced fat mass in obese mice receiving AOD-9604 without changes in lean body mass or tibial bone growth plate markers [7]. Rodent findings do not confirm human safety, and they especially do not address the hormonal milieu of a pubescent teenager whose hypothalamic-pituitary-gonadal and GH axes are both in active flux.

No Registered Pediatric Trials

A search of ClinicalTrials.gov as of mid-2025 returns zero active, recruiting, or completed interventional trials of AOD-9604 in participants under 18 years old [8]. This absence matters: FDA approval pathways for pediatric drugs under the Pediatric Research Equity Act (PREA) require dedicated pediatric studies before labeling can include a pediatric population [9].

Mechanism of Action: Growth Hormone Biology in Adolescents

AOD-9604 mimics the lipolytic domain of hGH by binding to adipocyte receptors and activating beta-3 adrenergic pathways that stimulate lipolysis. Adult studies suggest it does this without activating the IGF-1 receptor, which is how native hGH promotes linear bone growth and protein synthesis.

Why IGF-1 Neutrality Is Not Enough Reassurance in Teens

Even if AOD-9604 truly does not activate IGF-1 signaling, that finding was established in adults with closed epiphyseal plates. Adolescents between ages 12 and 17 have open or incompletely fused growth plates, and the GH axis is physiologically amplified during puberty. Circulating IGF-1 levels in Tanner stage 3 to 4 adolescents routinely exceed 400 ng/mL, compared with 150 to 250 ng/mL in healthy adults [10].

Any exogenous peptide interacting with GH-axis receptors in this context could, in theory, affect the timing of epiphyseal closure, pubertal tempo, or the feedback loop between the pituitary and the hypothalamus. That theoretical risk has not been ruled out by any published adolescent study.

Lipid Metabolism During Puberty

Puberty itself drives transient changes in lipid metabolism, insulin sensitivity, and adipokine signaling. Adding a lipolytic peptide to an already-shifting metabolic environment introduces interactions that no current model has characterized. A 2018 review in the Journal of Clinical Endocrinology and Metabolism noted that GH secretion peaks during mid-puberty at roughly twice the adult rate, making the GH axis particularly sensitive to exogenous interference during these years [10].

Regulatory and Compounding Status

AOD-9604 is not an FDA-approved drug. It is not on any FDA-recognized list of bulk substances permitted for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [2].

FDA's Position on Compounded Peptides

The FDA issued guidance in 2023 clarifying that peptides compounded without an approved drug equivalent are subject to new drug application requirements and cannot be compounded under the 503A exemption without appearing on the agency's bulks list [2]. Prescribing AOD-9604 to a teenager from a compounding pharmacy therefore carries regulatory risk for the prescriber and purity risk for the patient, since compounded peptides are not subject to the same manufacturing quality controls as approved drugs.

What Informed Consent Must Cover for Off-Label Prescribing

AMA Code of Medical Ethics Opinion 1.2.2 states that off-label prescribing is ethical when the physician has sound scientific evidence and clinical rationale to support the use, discloses the unapproved nature of the treatment, and obtains informed consent [11]. For AOD-9604 in adolescents, the scientific evidence requirement is not met given the absence of pediatric trials. Consent alone does not make a clinically unjustified prescription appropriate.

FDA-Approved Alternatives for Adolescent Obesity

Several approved options exist for adolescents aged 12 and older, and none of the evidence gaps that characterize AOD-9604 apply to these agents.

Semaglutide 2.4 mg (Wegovy)

The STEP TEENS trial (N=201, ages 12 to 17) demonstrated that semaglutide 2.4 mg weekly produced a 16.1% reduction in BMI from baseline at 68 weeks, compared with a 0.6% increase in the placebo group (P<0.001) [1]. The FDA approved Wegovy for adolescents aged 12 and older in December 2022. Common adverse effects were nausea (62%), vomiting (36%), and diarrhea (31%), consistent with the adult profile.

Orlistat

Orlistat 120 mg three times daily is FDA-approved for obesity in patients aged 12 and older. A Cochrane review of pediatric and adolescent trials found orlistat produced modest BMI reductions of approximately 0.7 to 0.8 kg/m² beyond placebo, with a well-established gastrointestinal side-effect profile [12]. Orlistat inhibits pancreatic lipase and reduces dietary fat absorption by roughly 30%.

Phentermine/Topiramate ER

Phentermine/topiramate ER received FDA approval for adolescents aged 12 and older (BMI ≥ 95th percentile) in 2022. The CONVOY trial (N=113) demonstrated 7.1% greater reduction in BMI compared with placebo over 56 weeks [13]. Teratogenicity risk requires pregnancy testing in female adolescents before and during use, per the drug's REMS program.

Clinical Decision Framework: Should Any Clinician Ever Prescribe AOD-9604 to an Adolescent?

The short answer, based on current evidence, is no. Below is a structured evaluation of the conditions that would need to be met before off-label prescribing could even be ethically considered under AMA and AAP standards.

Condition 1: Credible Mechanism With Adolescent-Relevant Data

For off-label use to have scientific rationale, the mechanism must have been tested in a population reasonably similar to the target group. AOD-9604 mechanism studies are primarily rodent-based or in adult humans. Adolescents differ physiologically in ways directly relevant to this peptide's activity, specifically GH axis amplitude, growth-plate status, and pubertal hormone interactions. This condition is not currently met.

Condition 2: A Positive Benefit Signal in Any Human Trial

The adult CP-METOB trial did not show significant weight loss. The absence of even an adult efficacy signal means the benefit side of a risk-benefit analysis for adolescents is speculative. This condition is not met.

Condition 3: Characterized Pediatric Safety Profile

No safety data exist for AOD-9604 in patients under 18. Known unknowns include effects on epiphyseal plate closure, pubertal timing, hypothalamic-pituitary feedback, and long-term metabolic trajectory. This condition is not met.

Condition 4: Failure of Approved Alternatives

The AAP 2023 guideline recommends that pharmacotherapy be considered only after intensive health behavior and lifestyle treatment, and it specifically endorses semaglutide and orlistat as first-line agents where pharmacotherapy is appropriate [6]. Prescribing an experimental peptide before trying approved agents with demonstrated pediatric safety data cannot be justified under a failure-of-alternatives rationale.

Monitoring If a Patient Has Already Received AOD-9604

Some adolescents may present having already received AOD-9604 from a compounding pharmacy, often without full disclosure of its unproven status. Clinicians encountering these patients should take the following steps.

Baseline and Follow-Up Labs

Order a fasting insulin, IGF-1, and insulin-like growth factor binding protein-3 (IGFBP-3) at presentation. Compare against Tanner-stage-specific normative ranges published in the 2011 JCEM reference interval study by Bidlingmaier and colleagues [14]. Abnormal values warrant immediate discontinuation and endocrinology referral.

Growth Assessment

Document height, weight, and bone age (left-hand radiograph if indicated) at presentation and again at 6 months. Any deceleration in linear growth velocity below the expected Tanner-stage trajectory requires endocrinology evaluation [6].

Discontinuation

There is no established tapering protocol for AOD-9604 because it was never approved. Given its short half-life of approximately 30 minutes in adult pharmacokinetic studies, abrupt discontinuation is not expected to produce a physiologic withdrawal syndrome [5]. Stop the agent, document the decision in the chart, and transition the patient to an evidence-based treatment plan.

What Parents and Patients Should Know

Teenagers and their families frequently encounter AOD-9604 through social media channels where it is described as "a safer growth hormone" or "a fat-loss peptide with no side effects." These characterizations are not supported by published clinical evidence.

The FDA has not approved AOD-9604 for any use in any age group [2]. The peptide's only human efficacy trial in adults did not demonstrate significant weight loss [4]. No adolescent safety data exist. Approved options for teens with obesity are available and have passed rigorous clinical trials: semaglutide (Wegovy) showed a 16.1% BMI reduction in the STEP TEENS trial [1], and topiramate/phentermine ER showed a 7.1% additional BMI reduction in the CONVOY trial [13].

"The evidence to support pharmacological treatment of obesity in children and adolescents must come from well-designed pediatric trials, not extrapolation from adult data," states the AAP 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity [6].

Summary of Risk Factors Specific to the 12 to 17 Age Group

Adolescents face biology-specific risks that adults do not when receiving GH-axis-active compounds. The following table outlines the primary concerns.

| Risk Domain | Mechanism | Evidence Status | |---|---|---| | Epiphyseal plate closure | GH/IGF-1 receptor stimulation may accelerate fusion | Uncharacterized for AOD-9604 | | Pubertal timing | Hypothalamic-pituitary feedback disruption | No data | | Linear growth | Premature growth-plate fusion | Theoretical; no trials | | Insulin sensitivity | Lipolysis-driven FFA elevation may impair glucose uptake | Possible; no pediatric data | | Purity/dose accuracy | Compounded products lack NDA quality controls | FDA concern documented [2] |